Obesity, Heart Failure, and SGLT2 Inhibition Obesity, Heart Failure, and SGLT2 Inhibition
A new analysis reveals that the SGLT2 inhibitor dapagliflozin produces a greater reduction in incident hospitalization for heart failure in obese patients compared with their non-obese counterparts.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 21, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
SGLT2 Inhibitors in Focal Segmental Glomerulosclerosis SGLT2 Inhibitors in Focal Segmental Glomerulosclerosis
This editorial explores the question of whether SGLT2 inhibitors could offer a potential treatment option for focal segmental glomerulosclerosis.Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 20, 2022 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news
Sep 16 This Week in Cardiology Sep 16 This Week in Cardiology
The safety of very low LDL-C, the win-ratio analytic method, sacubitril/valsartan, SGLT2 inhibitors, and percutaneous left atrial appendage closure are discussed in this week ’s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 16, 2022 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Advances in Diabetes and Heart Disease From ESC 2022 Advances in Diabetes and Heart Disease From ESC 2022
The mortality risk of diabetes, the consistent efficacy of dapagliflozin, and adherence to SGLT2 inhibitors and GLP-1R agonists are some highlights from ESC 2022 chosen by Professor Pardeep Jhund.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 14, 2022 Category: Consumer Health News Tags: None ReCAP Source Type: news
Prescribing of Newer Diabetes Drugs Not Up to Snuff in Black Patients?
(MedPage Today) -- Prescriptions for SGLT2 inhibitors and GLP-1 receptor agonists were not equitable across racial groups, according to an analysis of Veterans Health Administration (VHA) data.
Compared with white patients, Black patients had... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - September 6, 2022 Category: Primary Care Source Type: news
DELIVERing the Details on Dapagliflozin in Heart Failure DELIVERing the Details on Dapagliflozin in Heart Failure
Drs Pina and Solomon discuss the DELIVER trial presented at the European Society of Cardiology and whether all patients with heart failure should get SGLT2 inhibitors regardless of ejection fraction.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 2, 2022 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
SGLT2 Inhibitors Benefit Broad Range of Heart Failure Patients
FRIDAY, Sept. 2, 2022 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitors cut the risk for cardiovascular death and hospitalization for heart failure in patients with heart failure, regardless of ejection fraction, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 2, 2022 Category: Pharmaceuticals Source Type: news
Early Signal of Benefit for Empagliflozin in Acute MI: EMMY Early Signal of Benefit for Empagliflozin in Acute MI: EMMY
The findings increase optimism that SGLT2 inhibitors may provide clinical benefit to the post-MI population, observers say.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 2, 2022 Category: Endocrinology Tags: Cardiology News Source Type: news
SGLT2 Inhibitors Lower NAFLD, HCC Risks Over DPP4i SGLT2 Inhibitors Lower NAFLD, HCC Risks Over DPP4i
Sodium glucose cotransporter 2 inhibitors (SGLT2is) lowered the risk of nonalcoholic fatty liver disease and hapatocellular carcinoma versus dipeptidyl-peptidase-4 inhibitors (DPP4is).First Look (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 1, 2022 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Milestone Reached for SGLT2 Inhibitor Aimed at Heart Attack Population
(MedPage Today) -- BARCELONA -- Starting patients on empagliflozin (Jardiance) in the acute phase of a large myocardial infarction (MI) resulted in improvements in surrogate markers of heart failure (HF) and heart function over the next half... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 30, 2022 Category: Cardiology Source Type: news
Dapagliflozin Cuts CV Risk in Heart Failure With Preserved LVEF
MONDAY, Aug. 29, 2022 -- For patients with heart failure with mildly reduced or preserved ejection fraction, the sodium glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the combined risk for worsening heart failure or cardiovascular... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 29, 2022 Category: Pharmaceuticals Source Type: news
Finally, A Foundational Heart Failure Drug That Works Across the Spectrum of EF
(MedPage Today) -- BARCELONA -- With a major win in DELIVER, dapagliflozin (Farxiga) closed the gap on the types of heart failure (HF) proven to be treated safely by SGLT2 inhibition.
People with HF with preserved (HFpEF) and mildly reduced... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 28, 2022 Category: Cardiology Source Type: news
Dapagliflozin's HFpEF Benefit Recasts HF Treatment: DELIVER Dapagliflozin's HFpEF Benefit Recasts HF Treatment: DELIVER
Results from DELIVER made dapagliflozin the third SGLT2 inhibitor to benefit patients with HFpEF, cementing a new, ejection fraction-agnostic management approach.MDedge News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 27, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
Do SGLT2 Inhibitors DELIVER in All Heart Failure? Do SGLT2 Inhibitors DELIVER in All Heart Failure?
The investigators of the DELIVER trial and others suggest that all patients with heart failure get SGLT2 inhibitors, but this cardiologist sees differing effects depending on ejection fraction.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 27, 2022 Category: Consumer Health News Tags: Cardiology Expert Column Source Type: news
Clinical Trial, Meta-Analysis Find Diabetes Drugs May Benefit All Heart Failure Patients
In a large-scale clinical trial, researchers from the Brigham found that dapagliflozin, an SGLT2 inhibitor, reduced the risk of cardiovascular death or worsening heart failure irrespective of ejection fraction; A meta-analysis also presented by Br (Source: BWH News)
Source: BWH News - August 26, 2022 Category: Hospital Management Source Type: news
